Donald Bobo, Jr. Sells 24,000 Shares of Edwards Lifesciences (NYSE:EW) Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Donald Bobo, Jr. sold 24,000 shares of the stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $83.84, for a total value of $2,012,160.00. Following the completion of the transaction, the vice president directly owned 21,266 shares of the company’s stock, valued at approximately $1,782,941.44. This represents a 53.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Edwards Lifesciences Trading Up 0.7%

Shares of EW opened at $86.47 on Friday. Edwards Lifesciences Corporation has a 52-week low of $65.94 and a 52-week high of $87.89. The stock has a market cap of $50.22 billion, a PE ratio of 47.25, a price-to-earnings-growth ratio of 2.24 and a beta of 0.94. The firm’s fifty day moving average is $82.74 and its two-hundred day moving average is $81.22. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The business had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. Edwards Lifesciences’s quarterly revenue was up 13.3% on a year-over-year basis. During the same quarter last year, the company earned $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Research analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

EW has been the topic of a number of analyst reports. Evercore reiterated an “outperform” rating and set a $94.00 price objective on shares of Edwards Lifesciences in a research report on Monday, January 5th. Piper Sandler reaffirmed an “overweight” rating and issued a $100.00 target price (up from $98.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. National Bank Financial set a $92.00 price target on Edwards Lifesciences in a report on Friday, October 31st. Robert W. Baird set a $90.00 price target on shares of Edwards Lifesciences in a research report on Monday, January 12th. Finally, Citigroup reissued a “buy” rating and issued a $101.00 price objective (up from $96.00) on shares of Edwards Lifesciences in a report on Thursday, December 11th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $96.14.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Econ Financial Services Corp acquired a new position in shares of Edwards Lifesciences during the 2nd quarter worth $889,000. Fjarde AP Fonden Fourth Swedish National Pension Fund increased its holdings in Edwards Lifesciences by 7.0% in the third quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 137,835 shares of the medical research company’s stock valued at $10,719,000 after buying an additional 9,069 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Edwards Lifesciences by 13.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 86,235 shares of the medical research company’s stock valued at $6,706,000 after buying an additional 10,078 shares in the last quarter. Arkadios Wealth Advisors acquired a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at approximately $300,000. Finally, Atlantic Union Bankshares Corp boosted its stake in shares of Edwards Lifesciences by 2,240.9% during the 3rd quarter. Atlantic Union Bankshares Corp now owns 11,892 shares of the medical research company’s stock worth $925,000 after acquiring an additional 11,384 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.